Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: Application of simulation to preclinical PK-PD study design

Pharmaceutical Research

Volumn 26, Issue 10, 2009, Pages 2259-2269

  Bender, Gregor ^a   Gosset, James ^b   Florian, Jeff ^c   Tan, Keith ^b   Field, Mark ^b   Marshall, Scott ^b   Dejongh, Joost ^d   Bies, Robert ^c   Danhof, Meindert ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d LAP and P Consultants BV   (Netherlands)

Author keywords

Neuropathic pain; Optimal sampling; Synergistic interaction; Trial simulation

Indexed keywords

DRUG METABOLITE; N METHYLSILDENAFIL; PREGABALIN; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; DRUG POTENTIATION; EXPERIMENTAL MODEL; LOADING DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION; STEADY STATE;

ANIMALS; COMPUTER SIMULATION; CROSS-OVER STUDIES; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID; MALE; MODELS, BIOLOGICAL; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 69949133676     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9942-y     Document Type: Article

References (50)

1. MP Jensen MJ Chodroff RH Dworkin 2007 The impact of neuropathic pain on health-related quality of life: review and implications Neurology. 68 15 1178 82
2. MS Chong B Brandner 2006 Neuropathic agents and pain. New strategies Biomed Pharmacother. 60 7 318 22
3. DA Francis AT Christopher BD Beasley 2006 Conservative treatment of peripheral neuropathy and neuropathic pain Clin Podiatr Med Surg. 23 3 509 30
4. I Gilron, et al. 2006 Neuropathic pain: a practical guide for the clinician CMAJ. 175 3 265 75
5. KC Jackson II 2006 Pharmacotherapy for neuropathic pain Pain Pract. 6 1 27 33
6. TJ Nurmikko M Haanpaa 2005 Treatment of postherpetic neuralgia Curr Pain Headache Rep. 9 3 161 7
7. M Stillman 2006 Clinical approach to patients with neuropathic pain C Cleve Clin J Med. 73 8 726 8 729-30, 733-6 passim
8. N Harden M Cohen 2003 Unmet needs in the management of neuropathic pain J Pain Symptom Manage. 25 5 S12 7 Supp 1
9. MM Backonja G Irving C Argoff 2006 Rational multidrug therapy in the treatment of neuropathic pain Curr Pain Headache Rep. 10 1 34 8
10. I Gilron MB Max 2005 Combination pharmacotherapy for neuropathic pain: current evidence and future directions Expert Rev Neurother. 5 6 823 30
11. DM Jonker, et al. 2005 Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo Pharmacol Ther. 106 1 1 18
12. JY Chien, et al. 2005 Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation AAPS Journal. 7 3 E544 59
13. R Miller, et al. 2005 How modeling and simulation have enhanced decision making in new drug development J Pharmacokinet Pharmacodyn. 32 2 185 97
14. DM Jonker, et al. 2007 Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia. 48 3 412 34
15. L Aarons, et al. 1996 Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies Eur J Clin Pharmacol. 49 4 251 4
16. M Geldof, et al. 2007 Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies Eur J Pharm Sci. 30 1 45 55
17. EI Ette, et al. 1995 Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies Pharm Res. 12 5 729 37
18. EI Ette, et al. 1995 Analysis of animal pharmacokinetic data: performance of the one point per animal design J Pharmacokinet Biopharm. 23 6 551 66
19. Anonymous 2004 Pregabalin (Pfizer) Curr Opin Investig Drugs. 5 1 82 9
20. G Zareba G Zareba 2005 Pregabalin: a new agent for the treatment of neuropathic pain Drugs Today (Barc). 41 8 509 16
21. DR Guay DRP Guay 2005 Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother. 3 4 274 87
22. BA Lauria-Horner, et al. 2003 Pregabalin: a new anxiolytic Expert Opin Investig Drugs. 12 4 663 72
23. N Hitiris, et al. 2006 Modern antiepileptic drugs: guidelines and beyond Curr Opin Neurol. 19 2 175 80
24. K Hamandi, et al. 2006 Pregabalin: a new antiepileptic drug for refractory epilepsy Seizure. 15 2 73 8
25. A Briganti, et al. 2005 Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction World J Urol. 23 6 374 84
26. SA Antoniu SA Antoniu 2006 Sildenafil citrate for the treatment of pulmonary arterial hypertension Expert Opin Pharmacother. 7 6 825 8
27. G Jackson, et al. 2005 Past, present, and future: a 7-year update of Viagra (sildenafil citrate) Int J Clin Pract. 59 6 680 91
28. Bender G, Gosset J, DeJongh J, Bies R, Danhof M. Simulations to guide mechanism based PK-PD moeling of a synergistic interaction in an animal model of neuropathic pain. Leiden Amsterdam Center for Drug Research Quadrenniel meeting on In-Vivo and In-Vitro Measurement and Modeling of Pharmcodynamics. Noordwijkerhout, Netherlands, April 26-29, 2006.
29. GM Meno-Tetang, et al. 2005 On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach Basic Clin Pharmacol Toxicol. 96 3 182 92
30. R Gieschke BG Reigner JL Steimer 1997 Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling Int J Clin Pharmacol Ther. 35 10 469 74
31. EI Ette PJ Williams 2004 Population pharmacokinetics I: background, concepts, and models Ann Pharmacother. 38 10 1702 6
32. R Gieschke JL Steimer 2000 Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development Eur J Drug Metab Pharmacokinet. 25 1 49 58
33. LB Sheiner 1984 The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods Drug Metab Rev. 15 1-2 153 71
34. LB Sheiner JL Steimer 2000 Pharmacokinetic/pharmacodynamic modeling in drug development Annu Rev Pharmacol Toxicol. 40 67 95
35. GJ Bennett, et al. 1988 A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man Pain. 33 1 87 107
36. D'Argenio D.Z., S.A., ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. 1997: Biomedical Simulations Resource, Los Angeles.
37. LB Sheiner B Rosenberg VV Marathe 1977 Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J Pharmacokinet Biopharm. 5 5 445 79
38. Beal B, Sheiner L, NONMEM user's guide, Part I. San FranCIIsco: University of California at San FranCIIsco. 1992.
39. U Wahlby EN Jonsson MO Karlsson 2002 Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis AAPS Pharmsci. 4 4 E27
40. SL Beal 2002 Commentary on significance levels for covariate effects in NONMEM J Pharmacokinet Pharmacodyn. 29 4 403 10 discussion 411-2
41. U Wahlby EN Jonsson MO Karlsson 2001 Assessment of actual significance levels for covariate effects in NONMEM J Pharmacokinet Pharmacodyn. 28 3 231 52
42. JR Wade SL Beal NC Sambol 1994 Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis J Pharmacokinet Biopharm. 22 2 165 77
43. JW Mandema D Verotta LB Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J Pharmacokinet Biopharm. 20 5 511 28
44. EI Ette, et al. 2003 Model appropriateness and population pharmacokinetic modeling J Clin Pharmacol. 43 6 610 23
45. J Parke NH Holford BG Charles 1999 A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models Comput Methods Programs Biomed. 59 1 19 29
46. EI Ette 1997 Stability and performance of a population pharmacokinetic model J Clin Pharmacol. 37 6 486 95
47. Y Yano SL Beal LB Sheiner 2001 Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn. 28 2 171 92
48. JDH Cooper DC Muirhead JE Taylore PR Baker 1997 Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high performance liquid chromatography J Chrom B. 701 87 95
49. O Pauver C Lugnier T Keravis R Marthan E Rousseau JP Savineau 2003 Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery Br J Pharamcol. 139 3 513 22
50. A Roy EI Ette 2005 A pragmatic approach to the design of population pharmacokinetic studies AAPS Journal. 7 2 E408 20